Q-omics provides the consensus-scored SEMA3A profile across patient tissues and cancer cell-line models. SEMA3A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SEMA3A is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, SEMA3A RNA expression shows 16,312 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where SEMA3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA3A survival associations across molecular data types. SEMA3A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA3A RNA expression–survival associations across cancer types. High SEMA3A expression shows unfavorable associations in KIRP, CESC, BLCA, LGG and KIRC, but favorable associations in CHOL. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SEMA3A RNA expression.
This table summarizes SEMA3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SEMA3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA3A shows lower tumor expression in BLCA and BRCA and higher tumor expression in HNSC, LUAD, LIHC and CHOL. The BLCA box plot shows higher SEMA3A RNA expression in normal versus tumor tissue (log2 FC = −1.360, t-test p = .003).
This table shows molecular features associated with SEMA3A in patient tissues and cancer cell lines. In patient samples, SEMA3A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
